Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution.
about
Interventions for treating osteonecrosis of the jaw bones associated with bisphosphonatesAtypical Femoral Fracture: 2015 Position Statement of the Korean Society for Bone and Mineral ResearchScreening, diagnosis and treatment of osteoporosis: a brief reviewSkeletal complications of bisphosphonate use: what the radiologist should knowPeriprosthetic bone loss: diagnostic and therapeutic approachesBisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) projectBilateral spontaneous inter-trochanteric fractures of proximal femurs.Atypical femoral fracture risk in patients treated with bisphosphonates.Association between alendronate and atypical femur fractures: a meta-analysis.Long-Term Alendronate Use Not without Consequences?Incidence of stress fractures of the femoral shaft in women treated with bisphosphonate.Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays.Lateral Femoral Bowing and the Location of Atypical Femoral Fractures.Case reports: subtrochanteric femoral stress fractures after prolonged alendronate therapy.Amelioration of type I diabetes-induced osteoporosis by parathyroid hormone is associated with improved osteoblast survivalLong-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis.Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension.Once-monthly risedronate for postmenopausal osteoporosisPredictors of atypical femoral fractures during long term bisphosphonate therapy: a case series & review of literatureLong term bisphosphonate therapy & atypical femoral fractures: a word of caution.Femoral insufficiency fractures associated with prolonged bisphosphonate therapy.Is surgery necessary for femoral insufficiency fractures after long-term bisphosphonate therapy?Zoledronic acid infusion for prevention and treatment of osteoporosisZoledronic acid: clinical utility and patient considerations in osteoporosis and low bone massHigher doses of bisphosphonates further improve bone mass, architecture, and strength but not the tissue material properties in aged ratsBisphosphonate remains highly localized after elution from porous implantsSubtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group ReportAtypical femoral diaphyseal and subtrochanteric fractures and their association with bisphosphonates.Discontinuation of alendronate and administration of bone-forming agents after surgical nailing may promote union of atypical femoral fractures in patients on long-term alendronate therapy.Osteoporotic Hip and Spine Fractures: A Current Review.NCCN Task Force Report: Bone Health in Cancer Care.Role of zoledronic acid in the prevention and treatment of osteoporosis.Bisphosphonates and atypical fractures of femur.Neridronic acid for the treatment of bone metabolic diseases.Nonoperative versus prophylactic treatment of bisphosphonate-associated femoral stress fractures.Diseases affecting bone quality: beyond osteoporosis.Femoral Shaft Cortical Pathology associated with longterm Alendronate Therapy: A New ClassificationCentral dislocation of the hip secondary to insufficiency fractureTrends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996-2007.Subtrochanteric fractures in bisphosphonate-naive patients: results from the HORIZON-recurrent fracture trial.
P2860
Q24236073-BAAD573C-A014-4AED-AC9F-FC4B13D80753Q26782834-76BDF7D4-FC0E-433C-8D51-12CC431595DBQ26996726-BD20B3C0-CE6D-4B4C-AA33-71B3EB985A28Q27010157-F2EF6018-CDDB-40FB-AD82-FF18E7A6E016Q27024847-307F3B86-3331-4B4A-B78C-B9D82373CC3DQ27026618-BF11B969-CE64-4417-854A-BEB3B8CB5979Q33561623-74DC4203-06AB-4360-A8CE-6960075388E7Q33582253-84E29E75-5EA4-45B4-B96C-F1763A158FD5Q33596535-B2AC87C2-62CA-4A57-ACDB-A34F249173DFQ33633821-FA353A26-68CC-404C-889A-01D95FD64DE8Q33660030-8A92D477-665C-4C43-82D7-495E85F58C29Q33715141-D75606E5-6938-40CC-8635-048325C76A81Q33781081-6DFD059B-480A-4ABC-A068-D73AB3C59618Q33898842-EA34177F-75EC-4F85-92B4-ACA97840847BQ33910434-5C1706E4-16F2-4E8C-8DDD-F91785475046Q34018048-3D961719-FFFC-42C7-A082-7D237156A3A8Q34041189-DED20ACB-59D5-4ACF-8E19-21E654852915Q34272000-F445D09E-3254-4341-AA68-D9A372ED2406Q34272136-685F05DA-A8FE-4F91-99F0-CEC29B72A195Q34272165-431F0C93-1DDC-49C7-81EA-6F7AEDD4DB7AQ34283690-54278002-E708-48D4-AE46-1F582F09BA2BQ34283772-B9AC874B-8603-4206-A10A-D7C9973C9640Q34345697-9011A88D-69FD-4EEC-9F78-A1906CA7A08EQ34389524-011FA424-C10B-422E-A3CC-F851DE97F7AFQ34411999-9FF774A3-39F7-46FB-AA38-6BC9304B578BQ34477058-6D5EB04B-6B64-4B19-9F6B-12676D12BFF5Q34486831-A831DBD6-3AF1-4580-BA79-F0014C72B51AQ34522484-A4197CFE-A7E6-4155-9D72-B6C7DCFDF943Q34545924-DE934784-51E5-4833-AE17-B116D06D094BQ34612653-1F954C0C-112C-4117-ADD1-CB6154318B85Q34617936-5A52166E-6FF4-4EE5-9843-3AEC7A2351AFQ34984177-2486650A-C7F8-4B3D-B98D-272259DB020BQ34986933-625B997C-2384-4812-B1CA-66048BE7DC7EQ35003623-00AC63C2-227F-4E99-98F3-1C407E0C0D80Q35036461-02BA5F13-6E77-4B7E-AA53-648B9F81A0BDQ35078847-8BDDECB8-0C87-4CB8-B031-3CD4E6B394E8Q35123236-FCD547B2-99DD-4E84-A771-A7E59EF7845AQ35128848-3D2A4CBE-8B19-4FBD-8422-31D0DCE49A9AQ35229889-2EFDEDE4-8F82-45FF-AE83-096118915289Q35549448-179799FA-8E10-420A-8CE7-5BC9A5A270E5
P2860
Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution.
@ast
Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution.
@en
type
label
Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution.
@ast
Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution.
@en
prefLabel
Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution.
@ast
Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution.
@en
P2093
P1476
Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution.
@en
P2093
P304
P356
10.1302/0301-620X.89B3.18146
P577
2007-03-01T00:00:00Z